Use of Morphine Gel Topically in Patients With Stage 2-3 Wounds

A Phase 3, Single-centered, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Trial of Morphine Sulfate Gel 0.1% in Patients With Stage 2-3 Wounds

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00755989

Enrollment

Registered

2008-09-19

Start date

2009-04-30

Completion date

2010-04-30

Last updated

2025-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wounds

Brief summary

Morphine gel applied topically to wounds will reduce wound pain and decrease patients use of oral and intravenous pain medications, therefore reducing side effects.

Detailed description

Patients will be randomized to receive either placebo (versa base gel) or morphine gel to wound. Patients receiving morphine gel will have a decrease in pain score and use less oral/intravenous pain medications.

Interventions

OTHERNone available

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Signed and dated consent form & HIPAA * \>/= 18 yo * Single stage 2-3 wound evaluated by our wound care team * Alert and oriented (thinking ability clear and intact, physician approval) * English language proficiency, likely to be able to participate in all scheduled evaluations

Exclusion criteria

* Allergy to morphine, codeine, or versa base * pts taking medications for acute condition, other than for the wound pain (can be taking chronic pain meds if current dose stable for past 3 mo) * Patients with neuropathies * Patients with respiratory conditions * Patients that are pregnant

Design outcomes

Primary

Measure	Time frame
Safety and efficacy with the use of morphine gel applied topically for pain control	1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026